Skip Navigation

Job Title

Job category


Search jobs by matching your skills with LinkedIn

Sign up for job alerts

Or search again

Search by city

Beijing, Beijing Municipality, China
Job reference: R-050938
Posted date: May. 30, 2019

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious diseases. We're proud to have a unique workplace culture that inspires innovation and collaboration. We believe in the potential of our people and you’ll develop beyond what you thought possible.

The new R&D Oncology organisation brings together early and late oncology teams, from discovery through to late-stage development, with oncology specific Regulatory and Biometrics groups.

You’ll be in a global pharmaceutical environment but also exposed to strong rigorous academic science. For example, every postdoc has an external academic mentor to ensure we are working and publishing at the highest level in a field. What’s more, you’ll have the support of a leading academic advisor, who’ll provide you with the guidance and knowledge you need to develop your career.

Concurrent chemoradiotherapy (cCRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). When combined with durvalumab, the progression-free survival is significantly increased compared to placebo. Sequential chemoradiotherapy (sCRT) is associated with improved survival over cCRT. However, the mechanisms of how cCRT improves response to durvalumab, or how sCRT improves survival over cCRT are still not fully illuminated. Because of the unpleasant side effects caused by cCRT and the possible immune-suppression induced by chemotherapy, sequential definitive radiotherapy (RT) and immunotherapy might be a new therapeutic strategy for unresectable stage III NSCLC.

Cancer is one of the greatest challenges facing medical science today. In our Oncology Team, you’ll push the boundaries of science every day to help overcome that challenge. We’ve been at the centre of some of the biggest breakthroughs in oncology. In lung cancer, for example, we’ve brought together complementary expertise to aid discovery and accelerate development in new medicines through a variety of partnerships and initiatives. We’re also early adopters of new technologies to support innovation, including CRISPR, genome editing techniques and a next-generation sequencing platform for companion diagnostics in oncology. But we’re not stopping there. With a world-class pipeline and some of the best experts in the industry, we’re in a great position to develop even more innovative therapeutic approaches.

This is the first study focus on ctDNA neoantigen and bTMB dynamic changes during chemo/radiation therapy in NSCLC. The study aims to prove that both cCRT and definitive radiotherapy lead to significate ctDNA neoantigen release, bTMB increase, together with increased peripheral activated T cell clones, in order to optimize RT & Durvalumab treatment strategies.

You’ll work in a selected China leading academic and or CRO research lab to perform in vitro and in vivo pre-clinical experiments to establish a neoantigen assessment model, and clinical studies to set up an assessment system for evolution of ctDNA neoantigen and bTMB dynamic changes during cCRT/sCRT.

Education and Experience Required


  • PhD degree
  • Medical science background and relevant Immuno-therapy knowledge  
  • Previous clinical experience in treatment of NSCLC patients in China


  • Oncology clinical trial experience

Skills and Capabilities required:

  • in vitro and in vivo experiment skill
  • Data analysis capability for clinical correlation
  • Perfect English paper written capability 

This is a 3 year programme.  2 years will be a Fixed Term Contract, with a 1 year extension which will be merit based.  The role will be based in Beijing China, with a competitive salary on offer. To apply for this position, please click the apply link below.

Advert opening date – 31st May 2019 / Advert closing date – 9th August 2019

AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law.

Postdoc Fellow - Evalute Neoantigen in NSCLC IO Treatment

Sign up for job alerts

If you would like to sign up for email job alerts for future roles with AstraZeneca or MedImmune you can do so using the form below. We will only use the details you provide below to inform you about future vacancies that match your search criteria if and when they become available. The details you provide on this page will not be used to send unsolicited communication and will not be sold to a third party.


You can select as many categories and locations as you wish.

Interested InSelect a job category from the list of options. Search for a location and select one from the list of suggestions. Finally, click “Add” to create your job alert.

  • Scientific, Beijing, Beijing Municipality, ChinaRemove
  • Post Doc, Beijing, Beijing Municipality, ChinaRemove